公开(公告)号：EP2041319A2

公开(公告)日：2009-04-01

申请号：EP07812927.7

申请日：2007-07-13

申请人： Epigenomics AG

发明人： LOFTON-DAY, Cathy ,  SLEDZIEWSKI, Andrew ,  LESCHE, Ralf ,  SCHUSTER, Matthias ,  DISTLER, Juergen ,  TETZNER, Reimo ,  HILDMANN, Thomas ,  MODEL, Fabian ,  SONG, Xiaoling

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/154

摘要： The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.

公开(公告)号：EP1831399B1

公开(公告)日：2009-08-05

申请号：EP05853011.4

申请日：2005-12-02

申请人： Epigenomics AG

发明人： COTTRELL, Susan ,  MODEL, Fabian ,  HAEFLIGER, Carolina ,  WEISS, Gunter ,  DISTLER, Jürgen ,  SLEDZIEWSKI, Andrew, Z. ,  SONG, Xiaoling ,  SKILLMAN, Thomas, L. ,  THOMAS, Jeffrey G.

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57434 ,  G01N2800/60

摘要： Particular aspects provide novel methods and compositions (e.g., nucleic acids, kits, etc.) having substantial utility for providing a prognosis of prostate cell proliferative disorders. In particular aspects, this is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.

公开(公告)号：EP1831399A2

公开(公告)日：2007-09-12

申请号：EP05853011.4

申请日：2005-12-02

申请人： Epigenomics AG

发明人： COTTRELL, Susan ,  MODEL, Fabian ,  HAEFLIGER, Carolina ,  WEISS, Gunter ,  DISTLER, Jürgen ,  SLEDZIEWSKI, Andrew, Z. ,  SONG, Xiaoling ,  SKILLMAN, Thomas, L. ,  THOMAS, Jeffrey G.

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57434 ,  G01N2800/60

摘要： Particular aspects provide novel methods and compositions (e.g., nucleic acids, kits, etc.) having substantial utility for providing a prognosis of prostate cell proliferative disorders. In particular aspects, this is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.